Castle Biosciences Q1 revenue up 18% to $26.9M; net loss widens to $24.6M; raises 2022 guidance

CASTLE BIOSCIENCES INC

2022-Q1 EPS reported -$0.97 revenue$26,852,000

Revenue $26.9M (+18% YoY); adjusted revenue $26.3M (+50% YoY); net loss ($24.6M) vs ($4.3M) prior year.
Total test reports 8,627 (+68% YoY); DecisionDx-Melanoma +48%, DecisionDx-SCC +117%.
2022 total revenue guidance raised to $118-123M from $115-120M.
Acquired AltheaDx/IDgenetix PGx test for mental health in April 2022; adds ~$5B TAM.
Operating cash flow ($21.4M) vs ($3.6M); adjusted EBITDA ($11.4M) vs $0.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.